Advertisement

Topics

Final NICE nod for Sanofi’s Gaucher therapy

05:50 EDT 29 Jun 2017 | PharmaTimes

Sanofi’s Cerdelga can now be funded on the NHS in England and Wales to treat type 1 Gaucher disease, after cost regulators issued final guidance backing ‘routine’ use of the therapy.

Original Article: Final NICE nod for Sanofi’s Gaucher therapy

NEXT ARTICLE

More From BioPortfolio on "Final NICE nod for Sanofi’s Gaucher therapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...